Glycobiosciences, Inc. v. Vichy Laboratories, Sa

District Court, District of Columbia·Decided January 11, 2023·No. Civil Action No. 2022-1264·Published

Opinion

UNITED STATES DISTRICT COURT FOR THE DISTRICT OF COLUMBIA

GLYCOBIOSCIENCES, INC., Plaintiff, Civil Action No. 22-1264 (BAH)

v. Chief Judge Beryl A. Howell VICHY LABORATORIES, S.A. and L’ORÉAL, S.A.

Defendants.

MEMORANDUM OPINION AND ORDER Plaintiff Glycobiosciences, Inc., a Canadian cosmetic and pharmaceutical company, owns two patented formulae that are allegedly being infringed by Vichy Laboratories, S.A. and L’Oréal, S.A. (collectively, “defendants”). 1 Plaintiff sued defendants, alleging claims of patent infringement. See 35 U.S.C. §101 et. seq. Defendants now move to dismiss, claiming, inter alia, that personal jurisdiction is lacking over them in this judicial district. For the reasons below, defendants’ motion to dismiss is granted, without prejudice.

I. BACKGROUND The relevant factual and procedural background is summarized below.

A. Factual Background

1 Vichy Laboratories S.A. is named as a defendant in this action, but defendants clarify that no entity with that name exists and that an entity named “Vichy LLC” is wholly owned by L’Oréal USA with “Vichy” used as a brand name. Defs.’Mot. at 5 (explaining that “Vichy” is “a brand used by L’Oréal USA and there is a separate LLC—named Vichy LLC—for that brand. L’Oréal USA is the only member of Vichy LLC and the LLC has no employees or operations.”). Plaintiff concedes that Vichy Laboratories S.A. does not exist, and Vichy LLC is merely part of L’Oréal USA. See Pl’s Opp’n at 1 n.1 (“Defendant Vichy Laboratories is apparently a non-entity that is simply a brand name of Defendant L’Oréal S.A. . . . Thus[,] the Defendants collapse back into L’Oréal S.A.”). Consequently, assessment of personal jurisdiction focuses only on L’Oréal S.A.

Plaintiff is a successful Canadian cosmetic and pharmaceutical company that owns the following two patents at issue: (1) Patent No. 9,821,005, issued by the U.S. Patent and Trademark Office (“USPTO”) to plaintiff on November 21, 2017, for the formula of a gel containing specific percentages of bio-fermented sodium hyaluronate, hydroxyethylcellulose, polyethylene glycol, methylparaben, and water, Pls.’ Compl. (“Compl.”), ¶¶ 1, 12, 17, ECF No. 1; and (2) Patent No. 10,322,142, issued by USPTO to plaintiff on June 18, 2019, for the formula of a polymer matrix composed of specific percentages of bio-fermented sodium hyaluronate, non-ionic polymer, polyethylene glycol, and water, along with the inclusion “of an active therapeutic ingredient in addition to the Hyaluronic Acid,” id. ¶¶ 1, 13, 18. Both patents expire on August 5, 2035. Id. ¶ 13.

L’Oréal S.A., a corporation with its principal place of business and headquarters in Clichy, France, allegedly sells and distributes products using formulas similar to those that plaintiff has patented. See Id. ¶ 3, 19. Specifically, L’Oréal S.A. manufactures, distributes, and sells three cosmetics under the name Revitalift, which “contain high concentrations of Hyaluronic Acid in a Polymer matrix which includes a non-ionic polymer and are formulations that have all of the elements of one or more of the claims of the Glyco Patents and/or have formulae that are equivalent to the claimed formulas.” Id. ¶ 14. Likewise, “Vichy manufactures and sells” three products under the name “Liftactiv,” each “contain[ing] high concentrations of Hyaluronic Acid in a Polymer matrix which includes a non-ionic polymer and are formulations that have all of the elements of one or more of the claims of the Glyco Patents and/or have formulae that are equivalent to the claimed formulas.” Id. ¶ 15.

L’Oréal S.A. sells and distributes these products in the United States, including in the District of Columbia, exclusively through L’Oréal d/b/a L’Oréal USA (“L’Oréal USA”). See id.

¶¶ 3–4, 6. Apart from the contacts of L’Oréal USA, the only other contact that L’Oréal S.A. has in the United States is allegedly that an “Assistant Vice President – DIPI International Head of Instrumental Cosmetics & Digital,” named Dr. Roy P. Diaz, works out of an office located at 111 Terminal Avenue in Clark, New Jersey. Pl.’s Opp’n, Ex. C at 1 (Email, dated on March 22, 2022, to plaintiff’s representative from Dr. Diaz with the latter’s job title and office address in the signature block of the email) (“Diaz Email”), ECF No. 22-1.

B. Procedural Background In an effort to resolve the dispute amicably, plaintiff contacted and presented the two patent licenses at issue to L’Oréal S.A., with a request that defendant stop selling the allegedly patent- infringing products. See Compl. ¶¶ 16, 24, 30, 36, 40. L’Oréal S.A. declined the request, see id., prompting plaintiff to initiate the instant lawsuit, claiming that defendants willfully infringed both patents. Id. at 10, ¶¶ A-G. Plaintiff seeks a permanent injunction, compensatory damages, enhanced damages, attorneys’ fees, prejudgment interest, and post judgment interest. Id. at 10, ¶¶ H-M.

Defendants timely moved to dismiss for lack of personal jurisdiction, improper service, and improper venue, see Defs.’ Mot. to Dismiss (“Defs.’ Mot”), ECF No. 10, which motion plaintiff opposes, see Pl.’s Opp’n to. Mot. to Dismiss (“Pl.’s Opp’n”), ECF No. 12. With briefing completed, see Defs.’ Reply Mem. in Supp. Mot. to Dismiss (“Defs.’ Reply”), ECF No. 13, defendants’ motion is now ripe for resolution. II. LEGAL STANDARD “Personal jurisdiction is ‘an essential element of the jurisdiction of a district . . . court,’

without which the court is ‘powerless to proceed to an adjudication.’” Jankovic v. Int’l Crisis Grp., 494 F.3d 1080, 1086 (D.C. Cir. 2007) (alteration in original) (quoting Ruhrgas AG v. Marathon Oil Co., 526 U.S. 574, 584 (1999)). To survive a motion to dismiss for lack of personal

jurisdiction, under Federal Rule of Civil Procedure 12(b)(2), the plaintiff must “make a prima facie showing of the pertinent jurisdictional facts.” Livnat v. Palestinian Auth., 851 F.3d 45, 56–57 (D.C. Cir. 2017) (quoting First Chi. Int’l v. United Exch. Co., 836 F.2d 1375, 1378 (D.C. Cir. 1988)). The prima facie showing requires specific factual allegations connecting each defendant to the forum. First Chi. Int'l, 836 F.2d at 1378. While the complaint’s factual allegations must be accepted as true, and all reasonable inferences must be drawn in plaintiff’s favor, Bernhardt v. Islamic Republic of Iran, 47 F.4th 856, 861 (D.C. Cir. 2022), mere conclusory statements and bare allegations are insufficient, Livnat, 851 F.3d at 57.

Unlike on a motion to dismiss pursuant to Federal Rule of Civil Procedure 12(b)(6), the court “may consider materials outside the pleadings in deciding whether to grant a motion to dismiss for lack of jurisdiction.” Jerome Stevens Pharms., Inc. v. FDA, 402 F.3d 1249, 1253 (D.C. Cir. 2005) (citing Herbert v. Nat’l Acad. of Scis., 974 F.2d 192, 197 (D.C. Cir. 1992)). Indeed, jurisdictional arguments may be premised on the “pleadings, bolstered by such affidavits and other written materials as [the parties] can otherwise obtain.” Mwani v. bin Laden, 417 F.3d 1, 7 (D.C. Cir. 2005). “When deciding personal jurisdiction without an evidentiary hearing—as here—the ‘court must resolve factual disputes in favor of the plaintiff.’” Livnat, 851 F.3d at 57 (quoting Helmer v. Doletskaya, 393 F.3d 201, 209 (D.C. Cir. 2004)). The Court, however, “‘need not accept inferences drawn by plaintiffs if such inferences are unsupported by the facts.’” Id. (quoting Helmer, 393 F.3d at 209). III. DISCUSSION Defendants argue that the Court lacks the power to adjudicate this dispute because L’Oréal S.A. is a foreign company whose contacts in the United States are solely through L’Oréal USA, which operates as a separate legal entity and is not a party to the lawsuit. According to defendants,

L’Oréal S.A. lacks the requisite minimum contacts in the United States to satisfy the requirements for personal jurisdiction under the Fifth Amendment’s Due Process Clause. Mot. at 6; Reply at 5; see also U.S. CONST. amend. V. 2 Defendants are right.

Free access — add to your briefcase to read the full text and ask questions with AI

Glycobiosciences, Inc. v. Vichy Laboratories, Sa, (D.D.C. 2023).

Glycobiosciences, Inc. v. Vichy Laboratories, Sa (Glycobiosciences, Inc. v. Vichy Laboratories, Sa) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

International Shoe Co. v. Washington
326 U.S. 310 (Supreme Court, 1945)
Ruhrgas Ag v. Marathon Oil Co.
526 U.S. 574 (Supreme Court, 1999)
Helmer, John v. Doletskaya, Elena
393 F.3d 201 (D.C. Circuit, 2004)
Mwani, Odilla Mutaka v. Bin Ladin, Usama
417 F.3d 1 (D.C. Circuit, 2005)
Jankovic v. International Crisis Group
494 F.3d 1080 (D.C. Circuit, 2007)
Goodyear Dunlop Tires Operations, S. A. v. Brown
131 S. Ct. 2846 (Supreme Court, 2011)
Victor Herbert v. National Academy of Sciences
974 F.2d 192 (D.C. Circuit, 1992)
Johnson-Tanner v. First Cash Financial Services, Inc.
239 F. Supp. 2d 34 (District of Columbia, 2003)
BPA International, Inc. v. Kingdom of Sweden
281 F. Supp. 2d 73 (District of Columbia, 2003)
United States Ex Rel. Scollick v. Narula
215 F. Supp. 3d 26 (District of Columbia, 2016)
Rivka Livnat v. Palestinian Authority
851 F.3d 45 (D.C. Circuit, 2017)
Mary Erwin-Simpson v. AirAsia Berhad
985 F.3d 883 (D.C. Circuit, 2021)
Ford Motor Co. v. Montana Eighth Judicial Dist.
592 U.S. 351 (Supreme Court, 2021)
Joshua Atchley v. Astrazeneca UK Limited
22 F.4th 204 (D.C. Circuit, 2022)
Dana Bernhardt v. Islamic Republic of Iran
47 F.4th 856 (D.C. Circuit, 2022)